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There is a memorandum of understanding between the Department 
of Paediatrics at Tygerberg Children’s Hospital, Cape Town, South 
Africa (SA), and the Cameroon Baptist Hospitals in Cameroon 
to support the Cameroon Baptist Hospitals’ paediatric oncology 
programme. A recent Cochrane review found a lack of information 
on the effective treatment of Kaposi’s sarcoma (KS) in children with 
chemotherapy and highly active antiretroviral therapy (HAART). [1] 
Published treatment guidelines for the management of KS in 
resource-limited settings include chemotherapy with the single drugs 
etoposide, thalidomide and vincristine, with two drugs, namely 
vincristine and bleomycin, and with three drugs, namely doxorubicin 
(Adriamycin), bleomycin and vinblastine sulphate.[2] An SA multi-
institutional review of HIV-positive children treated with HAART 
and unspecified chemotherapy schedules reported a 58% projected 
5-year survival rate.[3] In Malawi the combination of vincristine plus 
bleomycin resulted in a 50% 1-year survival rate.[4] We report the 
outcome of a prospective study in children with KS in Cameroon 
treated with ABV, together with HAART for those who were HIV-
positive. This combination of drugs was chosen because they have 
individual activity against KS, and because they were available in this 
resource-limited setting.
Methods
All patients diagnosed with KS at Banso, Mbingo and Mutengene 
Baptist hospitals in north-west and south-west Cameroon 
between October 2011 and August 2015 were staged according to 
Mitsuyasu. [5] Treatment was with an institutional review board-
approved protocol consisting of doxorubicin 10 mg/m2, bleomycin 
15 IU/m2 and vincristine 1.5 mg/m2 intravenously (ABV) every 
4  weeks for four cycles. Chemotherapy commenced 4 weeks after 
the initiation of HAART, which was continued indefinitely in 
HIV-positive patients together with daily co-trimoxazole prophy-
laxis. HAART consisted of triple antiretrovirals adapted for age 
and weight according to World Health Organization guidelines. 
Chemotherapy was given at 4-week intervals to limit toxicity. 
Vincristine 1.5 mg/m2 was continued every 4 weeks for four doses 
if remission was not achieved. A fine-needle aspirate (FNA) and 
CD4+ count were recommended investigations. Informed parental 
consent was obtained. Follow-up was achieved by outpatient visits, 
telephone calls and home visits. Treatment was free.
Results
Twelve patients, 10 boys and 2 girls aged 2 - 11 (median 7) years, 
were treated. Two HIV-negative patients presented with a localised 
skin lesion and localised lymphadenopathy, respectively. The 
HIV-positive patients presented with stage III (n=3), IVA (n=3) 
and IVB (n=4) disease. An FNA was performed in 7 patients, 
and a CD4+ count in 7 (median 144 (range 11 - 946) cells/µL). 
One HIV-negative patient received additional vincristine. Two 
deaths occurred, both in HIV-positive patients. One died from 
febrile neutropenia and pulmonary disease on day 48, while the 
other did not return after two courses of ABV, his family deciding 
in favour of traditional medicine, and died of progressive KS on 
day 390. Both these patients had a CD4+ count of <100/µL. Eight 
HIV-positive patients were in remission after 1.5 - 50 (median 30) 
months’ follow-up at the time of writing, and the 2 HIV-negative 
patients were in remission after 19 and 37 months’ follow-up, 
respectively. Table 1 sets out details of age, sex, stage, FNA, CD4+ 
count, treatment and outcome (December 2016). No patients were 
lost to follow-up.
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There is little published information on effective treatment of Kaposi’s sarcoma (KS) in children in low-income countries. We prospectively 
treated 12 patients with an institutional review board-approved protocol consisting of four monthly courses of doxorubicin (Adriamycin), 
bleomycin and vincristine sulphate (ABV), with highly active antiretroviral therapy (HAART) plus co-trimoxazole prophylaxis for those 
who were HIV-positive, with additional vincristine if remission was not achieved after 4 months. Maintenance HAART plus co-trimoxazole 
was given to all HIV-positive patients. A fine-needle aspirate and CD4+ count were done if possible, and staging was performed according 
to Mitsuyasu. Eight of ten HIV-positive patients with stage III - IVB disease, and both HIV-negative patients with stage I disease, were in 
remission after 473 - 1 490 (mean 939) days. One patient died after absconding during treatment, and one died from neutropenia-related 
pulmonary infection. ABV with or without HAART is an effective treatment option for children with KS.
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Discussion
Although the incidence of KS in some African countries is 
decreasing because of HAART, it remains an important cause of 
childhood cancer.[6] No effective chemotherapy for patients in low-
income countries has been published to date. We used the above 
chemotherapy agents because of their individual efficacy and their 
availability. Although the number of patients is small, treatment 
with ABV with or without HAART achieved good medium-term 
survival in HIV-positive and HIV-negative patients, with one 
possible treatment-related death.
Conclusion
Four cycles of ABV plus HAART in HIV-positive patients achieved 
good medium-term survival in patients with KS.
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(cells/µL) FNA Treatment Status
Follow-up 
(mo)
1 7, M I – KS ABV CR 37
2 6, M IVB + 240 KS HAART/ABV CR 44
3 7, M IIIB + 27 NT HAART/ABV CR 24
4 6, M IVB + 11 KS HAART/ABV Died 13
5 7, F IIIB + 144 KS HAART/ABV CR 49
6 2, M IVB + NT KS HAART/ABV CR 50
7 7, M IVB + 946 KS HAART/ABV CR 22
8 4, M IVA + 54 NS HAART/ABV Died 1.5
9 11, M I – NT ABV+ CR 19
10 9, M IIIB + NT NT HAART/ABV CR 49
11 12, M IVB + NT NT HAART/ABV CR 36
12 11, F IVB + 619 NT HAART/ABV CR 16
FNA = fine-needle aspirate; M = male; F = female; – = negative; + = positive; NT = not tested; NS = nonspecific; ABV = doxorubicin (Adriamycin), bleomycin and vincristine sulphate;  
HAART = highly active antiretroviral therapy; ABV+ = extended vincristine; CR = complete remission.
